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Abstract
Initiation of antiretroviral treatment decreased HIV related mortality and morbid-
ity. Virological failure (a condition defined when the plasma viral load of HIV infected 
individuals greater than 1000 RNA copies/ml based on two consecutive viral load 
measurements with adherence support) have an increased risk of clinical progression 
to acquired immune deficiency syndrome (AIDS) and death. Nowadays, combination 
of highly active antiretroviral therapy is recommended to decrease the likelihood of 
drug resistance. However, there is emergence of drug resistance and treatment failure 
during treatment. Hence, managing and detecting antiretroviral treatment response 
is important to monitor the effectiveness of medication and possible drug switching 
for treatment regimens. Additionally, mechanisms of drug resistance and factors 
associated with immunological and virological treatment failure should be addressed.
Keywords: immunological response, virologic response, adverse drug reactions, 
HAART, drug resistance, mechanism
1. Introduction
Globally, in 2017, there were about 20.9 million HIV patients receiving highly 
active antiretroviral therapy (HAART) [1]. The treatment is targeted at inhibiting 
viral attachment and replication leading to the recovery of immune function  
[2, 3]. Since the introduction of HAART in 1996, there is a decline in mortality and 
morbidity associated with HIV [4, 5]. Due to HAART, the impact of HIV infection 
decreased [6] due to viral suppression, restoring and preserving immune function, 
improving quality of life, and reducing HIV related morbidity and mortality along 
the course of treatment [7–9]. There are a number of problems associated with 
HAART, including emergence of drug resistance, difficulties of maintaining long-
term adherence, and drug-related toxicities [5] which lead to virological failure, 
immunological failure and clinical progression [10].
Virological failure increases the risk of clinical progression of HIV to AIDS 
[11]. World health organization (WHO) recommended combination therapy of 
HAART [12, 13]. The combination therapy improved the natural history of HIV 
infection from a life-ending event to a manageable chronic condition [14]. Adverse 
drug reactions (ADRs) associated with HAART resulted some considerable health 
consequences like co-morbidity with opportunistic infections [15–17].
Viral Outbreaks
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Occurrence of immunological failure of HIV infected individuals on HAART.
Treatment failure to first-line regimens resulting from ADRs creates the need 
for very expensive and difficult-to-implement second-line regimens. Second-line 
HAART regimens are not easily affordable and largely donor dependent in resource-
limited settings [18]. Effective viral suppression is targeted by UNAIDS to meet 
“90-90-90” in 90% of persons on HAART by 2020 [19]. Use of an effective and 
safer HAART regimen helps to promote maximal viral suppression and improved 
immunological and virological response [20, 21].
2.  Occurrence and determinants of immunological and virological 
failure
2.1  Prevalence of immunological failure/immune reconstitution among HIV 
infected individuals on HAART
Immune reconstitution is the immunological response of immune cells (mostly 
CD4+ T cells) due to initiation of HAART. The response is either success or failure. 
Previously conducted studies reported different rates of immunological failure 
among HIV infected individuals (Table 1).
The variation among the above studies might be explained due to the differences 
in patient adherence, differences to define immunological failure whereby some 
studies defined as the reduction in number of CD4 + T cell count to baseline or 
below, or persistently low CD4+ T cell count (below 100 cells/μL) [31] and others 
defined immunological failure as reduction in number of CD4+ T cell count to 
baseline or below severe immune suppression (CD4+ T cell count <200 cells/μL) 
[24, 25, 28, 30, 32, 33]. Other studies defined immunological failure as 50% decline 
of CD4+ T cells from treatment peak value [28, 34] or at least 30% decline from 
treatment peak value [28, 35].
Moreover, the prevalence of immunological failure can be expressed with 
person-years among the HIV patients on treatment. As per recent studies, the rate 
was 2.966 [22], 2.57 [36], 8.7 [37] and 8 [38] person-years. The variation among 
these reports might be due to the differences in treatment adherence and the pres-
ence of opportunistic infections (status of co-morbidity). Hence, the coverage of 
good adherence toward the HAART was one of the determining factors for immu-
nological success. The likelihood of having good adherence of HAART increases the 
treatment success rate considering the results of previous studies (Table 2).
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Treatment adherence differs among studies due to differences in psychosocial 
support of relatives or the society to strictly adhere to the treatment guidelines, 
stigma, and lack of commitment to take medications so that HIV patients might 
drop themselves from on course ART treatment, perceived feeling of unwellness 
from medication, and scaring of treatment side effects [31, 40, 41].
Previously, baseline CD4+ T cell counts were playing an important role for an 
HIV patient to initiate HAART. The median baseline CD4+ T cell counts for an HIV 
infected individual to start HAART is explained below (Table 3). However, nowa-
days, the target is to test and treat regardless of their CD4+ T cell counts.
2.2  Associated factors of immunological failure among HIV infected individuals 
on HAART
Poor adherence to HAART increased to experience failure in CD4+ T cell recov-
ery [22, 26, 28, 33, 43]. This allows increased viral replication which in turn increases 
infection of new CD4+ T cells and ultimately depletion of immune cells [41]. 
Additionally, lower baseline CD4+ T cell count is one of the determining factors for 
increased immunological failure because immune recovery mostly depends on the 
number of baseline CD4+ T cell counts [22, 29, 38]. The timing of HAART initia-
tion is important to optimize the CD4+ T cell immune response to medication [44]. 











Coverage of good treatment adherence of clients from different studies.
Number Median baseline CD4+ T cell counts Reference
1. 196 cells/μL [22]
2. 191 cells/μL [24]
3. 162 cells/μL [23]
4. 156 cell/μL [24]
5. 152 cells/μL [28]
6. 115 cells/μL [32]
7. 177 cells/μL [34]
8. 238 cell/μL [42]
Table 3. 




These reports may highlight that patients with low CD4+ T cell count have poor long 
term CD4+ T cell immune response [22].
TB/HIV co-infection worsen the rate of immunological failure [22, 25, 37, 45–48]. 
TB infection impairs cellular immune responses through MTB-induced apoptosis of 
CD4+ T cells which subsequently lead to depletion of CD4+ T cells [49]. Incidence 
of TB during the course of HAART decreased the likelihood of treatment adherence 
due to its high pill burden and side-effects [50]. Although the risk of acquiring TB 
remains elevated, much less is known about the effect of HAART on recurrent TB 
[51]. All in all, recurrences of TB are lower among HIV infected individuals with 
higher CD4+ T cell counts [52].
2.3  Occurrence of virological failure among HIV infected individuals on 
HAART
Virological failure among individuals on HAART is defined as plasma viral load of 
the HIV infected individual is greater than 1000 RNA copies/ml based on two consecu-
tive viral load measurements with adherence support [53]. The occurrence of virologi-
cal failure of HAART among HIV infected individuals is reported below (Table 4).
The variation might be due to the differences in cutoff values of viral RNA 
copies per ml of plasma to consider virological failure [60, 63, 70], the duration of 
follow-up, differences of co-morbidity, variations on the treatment adherence of 
HAART, clinical/immunological failure [61, 71], perinatally infected [67], lower 
mean age [65] and shorter duration on HAART [66].
2.4  Associated factors of virological failure among HIV infected individuals on 
HAART
Magnitude of virological failure of HAART is not the same for all HIV infected 
individuals. There are factors that affect the likelihood of virological failure like 


















Prevalence of virological failure of HAART among individuals infected with HIV.
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malnourishment and overweight [22, 54, 72, 73]. Abnormal body mass index (BMI) 
is significantly correlated with decreased CD4+ T cell counts that increases viral 
load by progressing into the advanced stage of the disease [74, 75].
Moreover, the occurrence of virological failure is higher among TB co-infected 
individuals [54, 76, 77]. Concurrent HAART and TB treatment increases the rate of 
virological failure due to impaired treatment adherence and pharmacokinetics drug 
reactions. Hence, clients on HAART with active TB should be prioritized for viral 
load monitoring and follow-up. Moreover, to prevent incident TB during ART INH 
prophylaxis is recommended. Increased viral copies compromise immunity and 
negatively affect treatment by contributing to the double burden side effects of TB 
and HIV [78].
Failure for an immune-reconstitution increases the rate of virological failure 
[54, 79–81]. This leads to an increase in viral replication [22]. Hence, it is a surrogate 
marker for virological failure. During HAART, detecting and monitoring immuno-
logical response should also be emphasized to prevent drug resistance [22, 82].
3. Immune reconstitution during chronic HAART
Despite the successful suppression of viral replication, some clients on HAART 
might fail to recover immune cells (immune reconstitution). It is estimated that half 
of HIV infected individuals on HAART might fail to reconstitute their CD4+ T cell 
counts to levels above 500 cells/μL. Additionally, up to 16% might fail to achieve 
a CD4+ T cell counts greater than 200 cells/μL, even with long term therapy of 
HAART [83]. There are factors determining rates of immune reconstitution includ-
ing older age [84], lower baseline CD4+ T cell counts prior to HAART [85], and 
co-infection with hepatitis C virus (HCV) and TB [86, 87].
3.1 HAART is the most effective strategy for successful immune reconstitution
Initiation of HAART in early stages of HIV infection is associated with not 
detectable viral load suggesting effective inhibition of viral replication  
[88, 89]. During treatment initiation (during the first 4 months of HIV infec-
tion), there is lower recovery of immune cells due to a narrow restorative time. 
It is explained that starting HAART initiates both the rate and extent of CD4+ T 
cells reconstitution [90].
While treating HIV infected individuals, combining cytokine, IL-7 therapy, 
prevents apoptosis of T cells and is required for naive T-cell survival. This increases 
CD4+ T cell counts among clients on treatment [91]. The T cells remain capable of 
responding to antigenic stimuli and produce cytokines after polyclonal and specific 
antigenic stimulation. Then repopulation appears to extend cells from thymus to 
effector sites of the immune system [92, 93].
4. HIV drug resistance
Detecting HIV drug resistance is one of the major limiting factors in the success-
ful treatment of HIV infection [94]. This includes genotypic and phenotypic assays. 
The genotypic detection is performed by matching results with lists of frequently 
updated HIV mutations that are known to confer drug resistance which are rela-
tively inexpensive. However, it can only identify documented HIV mutations and 
may not detect new mutations that arise in a particular HIV variant. Although it is 
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drug susceptibility of a particular HIV variant. It provides information on the sen-
sitivity of a particular HIV variant in comparison to a control isolate with full drug 
sensitivity. Moreover, there is inconsistency in interpreting the detected decrease in 
viral drug sensitivity into actual decreases in clinical sensitivity. Hence, it needs to 
have large-scale clinical trials for a correlation might be made between changes in 
phenotypic sensitivity and actual drug resistance [95].
Investigators have assessed the effectiveness of HIV drug resistance test-
ing in improving clinical response to pharmacotherapy, like the GART [96], the 
VIRADAPT [97] and the ARGENTA [98]. They reported that individuals whose 
drug selection was based on genotypic resistance testing had significantly lower 
viral loads than patients who did not receive resistance testing prior to starting 
therapy. This reflects reduced morbidity and mortality [97].
Several factors related to the life cycle and replication of HIV are key con-
tributors toward the rapid and widespread emergence of resistance. Initially, the 
reverse transcriptase enzyme is highly prone to errors during the process of reverse 
transcription. Hence it makes errors in each HIV genome per round of replication 
process which enhances its mutation for every 2000 nucleotide bases [99]. In addi-
tion to these base substitutions, insertions can occur. The especial scenario of HIV 
drug resistance mechanism is also due to high rate of replication. When untreated, 
plasma HIV RNA levels range from 103 to 105 copies/ml or sometimes greater than 
106 copies/ml in acute infection [100].
The HIV virus continues to infect new cells at a very high rate to maintain the 
infection to a stationary state. Additionally, increased rate of errors in the reverse 
transcription yields new variants with drug resistance. Some HIV variants manifest 
drug resistance due to intrinsic factors. Hence, antiretroviral resistance can still 
occur even during successful therapy of HIV infection [101].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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